Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 5/20 | 0.62 |
| ▸ | ACE | P12821 | 3/20 | 0.58 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.55 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ECE1 | P42892 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3147315 | 0.85 | MME (0.51) | MMEACEERCC1ERCC4ALDH1A1 | |
| SCHEMBL4385872 | 0.85 | MME (0.51) | MMEACEERCC1ERCC4ALDH1A1 | |
| SCHEMBL18255328 | 0.84 | ALDH1A1 (0.57) | MMEACEERCC1ERCC4ALDH1A1 | |
| SCHEMBL3143059 | 0.83 | GLI1 (0.65) | ALDH1A1MAPTLMNAPTGS2HPGD | |
| SCHEMBL19523017 | 0.83 | PKM (0.58) | ERCC1ERCC4ALDH1A1LMNAGRM7 | |
| SCHEMBL10138151 | 0.83 | PKM (0.58) | ERCC1ERCC4ALDH1A1LMNAGRM7 | |
| SCHEMBL27598564 | 0.82 | PTGS1 (0.65) | MMEACEERCC1ERCC4LMNA | |
| SCHEMBL1891876 | 0.82 | PTGS1 (0.65) | MMEACEERCC1ERCC4LMNA | |
| SCHEMBL14540295 | 0.82 | ERCC1 (0.52) | MMEACEERCC1ERCC4ALDH1A1 | |
| SCHEMBL3200580 | 0.82 | ERCC1 (0.52) | MMEACEERCC1ERCC4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12050228-B2 | Automated sample quality assessment | METABOLON, INC. (US) | 2024-07-30 | — | — | US | claimed |
| US-20230233620-A1 | HIGH-COMPLEXITY SYNTHETIC GUT BACTERIAL COMMUNITIES | Kanvas Biosciences, Inc. | 2023-07-27 | — | — | US | claimed |
| EP-4152959-A1 | HIGH-COMPLEXITY SYNTHETIC GUT BACTERIAL COMMUNITIES | Chan Zuckerberg Biohub, Inc. (US) | 2023-03-29 | — | — | EP | claimed |
| US-20220233611-A1 | COMPOSITIONS AND METHODS FOR PROMOTING HEALTHY NEURAL DEVELOPMENT IN AN UNBORN BABY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-07-28 | — | — | US | claimed |
| EP-3965820-A1 | COMPOSITIONS AND METHODS FOR PROMOTING HEALTHY NEURAL DEVELOPMENT IN AN UNBORN BABY | The Regents of the University of California (US) | 2022-03-16 | — | — | EP | claimed |
| US-20220050090-A1 | MASS SPECTROMETRY ASSAY METHOD FOR DETECTION AND QUANTITATION OF MICROBIOTA RELATED METABOLITES | METABOLON, INC. | 2022-02-17 | — | — | US | claimed |
| WO-2021237162-A1 | HIGH-COMPLEXITY SYNTHETIC GUT BACTERIAL COMMUNITIES | CHAN ZUCKERBERG BIOHUB, INC. (US) | 2021-11-25 | — | — | WO | claimed |
| US-20210353611-A1 | METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2021-11-18 | — | — | US | claimed |
| EP-3852759-A2 | METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS | Yeda Research and Development Co. Ltd (IL) | 2021-07-28 | — | — | EP | claimed |
| EP-3850359-A1 | MASS SPECTROMETRY ASSAY METHOD FOR DETECTION AND QUANTITATION OF MICROBIOTA-RELATED METABOLITES | Metabolon Inc. (US) | 2021-07-21 | — | — | EP | claimed |
| US-20170306504-A1 | CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME | CHAMPIONX LLC | 2017-10-26 | — | — | US | claimed |
| EP-3129909-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | Metabolon, Inc. (US) | 2017-02-15 | — | — | EP | claimed |
| WO-2015157407-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | METABOLON, INC. (US) | 2015-10-15 | — | — | WO | claimed |
| US-20150065366-A1 | Biomarkers for Bladder Cancer and Methods Using the Same | METABOLON, INC. | 2015-03-05 | — | — | US | claimed |
| EP-2776832-A1 | BIOMARKERS FOR BLADDER CANCER AND METHODS USING THE SAME | Metabolon, Inc. (US) | 2014-09-17 | — | — | EP | claimed |
| WO-2013070839-A1 | BIOMARKERS FOR BLADDER CANCER AND METHODS USING THE SAME | METABOLON, INC. (US) | 2013-05-16 | — | — | WO | claimed |
| EP-1047391-A4 | ALPHA-AMIDES OF L-AMINO ACIDS AS FRAGRANCE PRECURSORS | GILLETTE CO (US) | 2005-01-19 | — | — | EP | claimed |
| US-6238655-B1 | USEFUL IN THE FORMULATION OF DEODORANTS, ANTIPERSPIRANTS, BODY SPRAYS, AND OTHER SKIN TREATMENT COMPOSITIONS. | THE GILLETTE COMPANY | 2001-05-29 | — | — | US | claimed |
| EP-1047391-A1 | ALPHA-AMIDES OF L-AMINO ACIDS AS FRAGRANCE PRECURSORS | THE GILLETTE COMPANY (US) | 2000-11-02 | — | — | EP | claimed |
| WO-1999030679-A1 | α-AMIDES OF L-AMINO ACIDS AS FRAGRANCE PRECURSORS | THE GILLETTE COMPANY (US) | 1999-06-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353611-A1 | METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS | SMN1; SMN2, SOD1, OAT | MME 200/4885ACE 1145/4885ERCC1 3681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.